Moosdorf R, Maisch B, Höffken H
Klinikum der Philipps-Universität Marburg Klinik für Herchirurgie, Marburg.
Z Kardiol. 1996;85 Suppl 6:281-5.
Indications for interventional catheter techniques and bypass surgery have been extended to more complex lesions and also the number of reoperations after primary successful interventions has increased due to progression of the underlying disease. Finally a number of patients remains still symptomatic but, as a consequence of a very diffuse distribution of atherosclerotic lesions, is no longer accessible with conventional techniques of direct revascularization. This has drawn the attention again to indirect techniques of myocardial revascularization. Transmyocardial laserrevascularization offers a new option in reperfusing the ischemic myocardium via transmural channels from the ventricular cavity. As to the function of the channels, it is not quiet clear, wether they may connect to intramyocardial capillaries or may themselves induce a neoangiogenesis. However the clinical follow up in patients with intractable angina pectoris shows a significant improvement. At our hospital a number of 117 patients have been treated with this new method, 53 of them in conjunction with conventional bypass surgery. Clinical follow up after three and six months postoperatively showed a significant improvement concerning angina (CCS) and exercise tolerance (NYHA). This could also objectively be demonstrated by scintigraphy with an increased myocardial perfusion in 50% of the reinvestigated patients. Ischemic areas can still be seen, but occur at a significantly higher exercise level, demonstrating an improved but not normalized myocardial blood supply. The transmyocardial laserrevascularization is no alternative to well established procedures like PTCA or bypass surgery, but can be seen as a therapeutic option for those symptomatic patients recently being intractable. Further longterm studies and also experimental investigations have to evaluate the definitive role of this new treatment for endstage coronary heart disease.
介入导管技术和搭桥手术的适应证已扩展至更复杂的病变,而且由于基础疾病的进展,首次成功干预后的再次手术数量也有所增加。最后,仍有一些患者有症状,但由于动脉粥样硬化病变分布非常弥散,传统的直接血运重建技术已无法对其进行治疗。这再次引起了人们对心肌血运重建间接技术的关注。经心肌激光血运重建术为通过心室腔内的透壁通道使缺血心肌再灌注提供了一种新选择。至于这些通道的功能,目前尚不清楚它们是否可能与心肌内毛细血管相连,或者它们本身是否会诱导新生血管形成。然而,对顽固性心绞痛患者的临床随访显示有显著改善。在我们医院,有117例患者接受了这种新方法治疗,其中53例与传统搭桥手术联合进行。术后3个月和6个月的临床随访显示,心绞痛(加拿大心血管学会分级)和运动耐量(纽约心脏协会分级)有显著改善。这也可以通过闪烁扫描客观地证明,50%的再次检查患者心肌灌注增加。仍可看到缺血区域,但出现在明显更高的运动水平时,表明心肌血液供应有所改善但未恢复正常。经心肌激光血运重建术并非像经皮冠状动脉腔内血管成形术或搭桥手术等成熟手术的替代方法,但可被视为那些近期顽固性有症状患者的一种治疗选择。进一步的长期研究以及实验研究必须评估这种新治疗方法对终末期冠心病的确切作用。